Drugs / KL003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07436767 | Mar 2026 → Sep 2028 expected | sickle cell disease | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| — | NCT06219239 | Jan 2024 → Dec 2025 overdue | beta thalassemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT05860595 | May 2023 → Aug 2025 overdue | beta thalassemia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07436767 ↗ |
| Action | Restore | “the patient's autologous CD34⁺ hematopoietic stem cells are engineered to differentiate into red blood cells expressing functional β-globin, thereby increasing overall...” NCT07436767 ↗ |
| Modality | Cell therapy | “Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.” NCT05860595 ↗ |
| Route | Intravenous | “A single intravenous infusion of ≥ 3.0 × 10\^6 CD34+ cells/kg was administered.” NCT07436767 ↗ |